Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
The stock's rise snapped a four-day losing streak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback